Classification of 33 selected studies according to their main objectives and prospective or retrospective design
Groups of studies . | No. of studies . | Populations . | Patients . | Events . | IR for thrombosis, % (95% CI) . | Homogeneity test, P . |
|---|---|---|---|---|---|---|
| A* | 1071-80 | 11 | 1232 | 71 | 5.6 (4.3-7.1) | < .001 |
| B1*/B2* | 181 /670, 82-86 | 13 | 520 | 20 | 3.9 (2.3-5.9) | .32 |
| C | 987-95 | 9 | 126 | 0 | 0 (0-0.3) | NA |
| D | 796-102 | 9 | 5501 | 82 | 1.5 (1.2-1.8) | < .001 |
Groups of studies . | No. of studies . | Populations . | Patients . | Events . | IR for thrombosis, % (95% CI) . | Homogeneity test, P . |
|---|---|---|---|---|---|---|
| A* | 1071-80 | 11 | 1232 | 71 | 5.6 (4.3-7.1) | < .001 |
| B1*/B2* | 181 /670, 82-86 | 13 | 520 | 20 | 3.9 (2.3-5.9) | .32 |
| C | 987-95 | 9 | 126 | 0 | 0 (0-0.3) | NA |
| D | 796-102 | 9 | 5501 | 82 | 1.5 (1.2-1.8) | < .001 |
A indicates prospective studies designed for evaluating clinical thrombotic events; B1, prospective studies describing outcomes of therapeutic protocols, with reference to thrombotic events as complications; B2, prospective comparative studies or open randomized clinical trials comparing different doses or preparations of ASP (3),82-84 EC versus Erwinase ASP (2),85,86 or prophylaxis with anti—thrombin III versus no prophylaxis (1)70 ; C, prospective studies designed for the evaluation of laboratory parameters of hypercoagulability that describe clinical thrombotic complications as additional information; and D, retrospective studies.
Studies included in the Final Prospective Model.